$VYGR
Voyager Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022016733 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $40.91M $41.09M
YoY Change 45.72% 2672.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $30.98M $7.307M
YoY Change 270.97% -16.15%
% of Gross Profit
Research & Development $60.76M $19.34M
YoY Change 333.41% 7.94%
% of Gross Profit
Depreciation & Amortization $834.0K $1.341M
YoY Change -43.72% 9.56%
% of Gross Profit
Operating Expenses $91.74M $26.64M
YoY Change 310.1% 0.06%
Operating Profit $14.44M
YoY Change -157.43%
Interest Expense $1.792M $545.0K
YoY Change -378.69% 350.41%
% of Operating Profit 3.77%
Other Income/Expense, Net $2.653M $3.182M
YoY Change 308.15% 35255.56%
Pretax Income -$46.39M $17.62M
YoY Change -912.61% -170.11%
Income Tax $16.00K
% Of Pretax Income
Net Earnings -$46.41M $17.62M
YoY Change -912.89% -170.11%
Net Earnings / Revenue -113.45% 42.9%
Basic Earnings Per Share $0.46
Diluted Earnings Per Share -$1.21 $0.45
COMMON SHARES
Basic Shares Outstanding 38.61M 38.65M
Diluted Shares Outstanding 39.57M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $118.8M $131.6M
YoY Change -10.33% 8.34%
Cash & Equivalents $98.96M $96.86M
Short-Term Investments $19.89M $34.78M
Other Short-Term Assets $4.233M $5.079M
YoY Change 148.85% 43.47%
Inventory
Prepaid Expenses
Receivables $257.0K $10.23M
Other Receivables $0.00 $0.00
Total Short-Term Assets $124.5M $146.9M
YoY Change -8.92% 16.43%
LONG-TERM ASSETS
Property, Plant & Equipment $17.86M $18.08M
YoY Change -18.54% -21.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.515M $1.515M
YoY Change -14.84% -14.84%
Total Long-Term Assets $34.86M $35.54M
YoY Change -39.02% -39.32%
TOTAL ASSETS
Total Short-Term Assets $124.5M $146.9M
Total Long-Term Assets $34.86M $35.54M
Total Assets $159.4M $182.5M
YoY Change -17.8% -1.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.566M $1.337M
YoY Change 347.04% 125.84%
Accrued Expenses $7.816M $12.53M
YoY Change -28.62% 10.64%
Deferred Revenue $59.38M $56.63M
YoY Change 75.23% 493.79%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.59M $73.24M
YoY Change 42.39% 174.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $21.30M $22.02M
YoY Change -46.24% -46.3%
Total Long-Term Liabilities $21.30M $22.02M
YoY Change -46.24% -46.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.59M $73.24M
Total Long-Term Liabilities $21.30M $22.02M
Total Liabilities $100.3M $102.7M
YoY Change 1.55% 5.45%
SHAREHOLDERS EQUITY
Retained Earnings -$393.5M -$369.9M
YoY Change 13.37% 4.85%
Common Stock $38.00K $38.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.02M $79.82M
YoY Change
Total Liabilities & Shareholders Equity $159.4M $182.5M
YoY Change -17.8% -1.24%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$46.41M $17.62M
YoY Change -912.89% -170.11%
Depreciation, Depletion And Amortization $834.0K $1.341M
YoY Change -43.72% 9.56%
Cash From Operating Activities -$12.24M -$16.21M
YoY Change -209.37% -21.74%
INVESTING ACTIVITIES
Capital Expenditures $933.0K -$278.0K
YoY Change -368.88% -57.88%
Acquisitions
YoY Change
Other Investing Activities $15.00M $35.00M
YoY Change -393.14% 133.33%
Cash From Investing Activities $14.07M $34.72M
YoY Change -357.45% 142.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 276.0K 15.00K
YoY Change 21.59%
NET CHANGE
Cash From Operating Activities -12.24M -16.21M
Cash From Investing Activities 14.07M 34.72M
Cash From Financing Activities 276.0K 15.00K
Net Change In Cash 2.099M 18.53M
YoY Change -64.77% -390.96%
FREE CASH FLOW
Cash From Operating Activities -$12.24M -$16.21M
Capital Expenditures $933.0K -$278.0K
Free Cash Flow -$13.18M -$15.93M
YoY Change -214.17% -20.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2746000
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38607346
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96860000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
34778000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15106000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
10000000
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
225000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5079000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3427000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
146942000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
136698000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18082000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21920000
CY2022Q3 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2021Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1779000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15941000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33458000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1337000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
574000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12529000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56630000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33886000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
73242000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50981000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8210000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22024000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2022Q3 us-gaap Liabilities
Liabilities
102657000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38520336
CY2022Q3 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssets
CY2021Q4 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssets
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001640266
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37918395
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37625
dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
dei Entity Address Address Line1
EntityAddressAddressLine1
64 Sidney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
259-5340
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
VYGR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38607346
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96860000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
34778000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15106000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
10000000
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
225000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5079000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3427000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
146942000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
136698000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18082000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21920000
CY2022Q3 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2021Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1779000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15941000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33458000
CY2022Q3 us-gaap Assets
Assets
182480000
CY2021Q4 us-gaap Assets
Assets
193855000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1337000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
574000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12529000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2746000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56630000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33886000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
73242000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50981000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7391000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8210000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22024000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2022Q3 us-gaap Liabilities
Liabilities
102657000
CY2021Q4 us-gaap Liabilities
Liabilities
98800000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38520336
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37918395
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
450008000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442259000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-337000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369886000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347104000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
79823000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182480000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
193855000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41086000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28895000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
26644000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
26628000
us-gaap Operating Expenses
OperatingExpenses
68731000
us-gaap Operating Expenses
OperatingExpenses
88662000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
14442000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38520336
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37918395
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26274000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79320000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
545000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
121000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
816000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2676000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1482000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
450008000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442259000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-337000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369886000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347104000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
79823000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182480000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
193855000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41086000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1482000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42457000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19337000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17914000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46213000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59767000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7307000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8714000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22518000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2161000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3182000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3492000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2414000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
17624000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25137000
us-gaap Net Income Loss
NetIncomeLoss
-22782000
us-gaap Net Income Loss
NetIncomeLoss
-76906000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-199000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42457000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9342000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19337000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17914000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46213000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59767000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7307000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8714000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22518000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28895000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
26644000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
26628000
us-gaap Operating Expenses
OperatingExpenses
68731000
us-gaap Operating Expenses
OperatingExpenses
88662000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
14442000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26274000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79320000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
545000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
121000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
816000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
253000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2637000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2676000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2161000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3182000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3492000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2414000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
17624000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25137000
us-gaap Net Income Loss
NetIncomeLoss
-22782000
us-gaap Net Income Loss
NetIncomeLoss
-76906000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-199000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-199000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17651000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25139000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22981000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76900000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-199000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17651000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25139000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22981000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76900000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37780547
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623309
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39570394
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37780547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38292497
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623309
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21649000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
580000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3871000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30120000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
110536000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2025000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25137000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
87422000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2268000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
75931000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
575000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
313000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2460000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19087000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37780547
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623309
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39570394
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37780547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38292497
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623309
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21649000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
580000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3871000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30120000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
110536000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2025000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25137000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
87422000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2268000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
75931000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
575000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
313000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2460000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19087000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60051000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2106000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
17624000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
79823000
us-gaap Profit Loss
ProfitLoss
-22782000
us-gaap Profit Loss
ProfitLoss
-76906000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60051000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2106000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
17624000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
79823000
us-gaap Profit Loss
ProfitLoss
-22782000
us-gaap Profit Loss
ProfitLoss
-76906000
us-gaap Share Based Compensation
ShareBasedCompensation
6998000
us-gaap Share Based Compensation
ShareBasedCompensation
9670000
us-gaap Depreciation
Depreciation
5357000
us-gaap Depreciation
Depreciation
3683000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
23000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-324000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2468000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2460000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-507000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-6847000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1652000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1731000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3005000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2265000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
763000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-42000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1536000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2912000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3280000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2348000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-151000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21925000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4641000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-265000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64720000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1558000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1262000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
54848000
vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
35000000
vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
72632000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
71370000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
602000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
232000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
357000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
834000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
385000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20837000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7035000
us-gaap Share Based Compensation
ShareBasedCompensation
6998000
us-gaap Share Based Compensation
ShareBasedCompensation
9670000
us-gaap Depreciation
Depreciation
5357000
us-gaap Depreciation
Depreciation
3683000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
23000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-324000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2468000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2460000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-507000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-6847000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1652000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1731000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3005000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2265000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
763000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-42000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1536000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2912000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3280000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2348000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-151000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21925000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4641000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-265000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64720000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1558000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1262000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
54848000
vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
35000000
vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
72632000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
71370000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
602000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
232000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
357000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
834000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
385000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20837000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7035000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98375000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113254000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
40000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a<span style="font-size:11pt;"> </span>biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of<span style="font-family:'Segoe UI';"> </span>either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company's three prioritized pipeline programs include: GBA1 gene therapy for Parkinson’s disease, SOD1 gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease. The Company plans to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug (IND) filings expected in 2024 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to these three lead programs, the Company has a collaboration ongoing with <span style="background:#ffffff;">Neurocrine Biosciences, Inc. (“Neurocrine”) </span>to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, the Company has an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to the Company, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and other biological therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing <span style="background:#ffffff;">collaboration with Neurocrine under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including option and license agreements related to the TRACER capsids such as the Company’s October 2021 option and license agreement with Pfizer Inc. </span>(“Pfizer”), pursuant to which Pfizer exercised an option effective as of September 30, 2022, and the Company’s March 2022 option and license agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">programs and option and license transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of September 30, 2022, the Company had an accumulated deficit of $369.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, <span style="font-family:'Times';">its option and license agreement with Pfizer, and its option and license agreement with Novartis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $131.6 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million received in the fourth quarter of 2022 will be sufficient to meet the Company’s planned operating expenses and capital expenditure re<span style="background:#ffffff;">quirements</span> into 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369900000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
131600000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21024000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38608000
CY2022Q3 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98375000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113254000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
40000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a<span style="font-size:11pt;"> </span>biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of<span style="font-family:'Segoe UI';"> </span>either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company's three prioritized pipeline programs include: GBA1 gene therapy for Parkinson’s disease, SOD1 gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease. The Company plans to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug (IND) filings expected in 2024 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to these three lead programs, the Company has a collaboration ongoing with <span style="background:#ffffff;">Neurocrine Biosciences, Inc. (“Neurocrine”) </span>to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, the Company has an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to the Company, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and other biological therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing <span style="background:#ffffff;">collaboration with Neurocrine under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including option and license agreements related to the TRACER capsids such as the Company’s October 2021 option and license agreement with Pfizer Inc. </span>(“Pfizer”), pursuant to which Pfizer exercised an option effective as of September 30, 2022, and the Company’s March 2022 option and license agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">programs and option and license transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of September 30, 2022, the Company had an accumulated deficit of $369.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, <span style="font-family:'Times';">its option and license agreement with Pfizer, and its option and license agreement with Novartis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $131.6 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million received in the fourth quarter of 2022 will be sufficient to meet the Company’s planned operating expenses and capital expenditure re<span style="background:#ffffff;">quirements</span> into 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
vygr Collaborative Arrangement Number Of Programs
CollaborativeArrangementNumberOfPrograms
3
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369900000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
131600000
CY2022Q3 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
128030000
CY2022Q3 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
209000
CY2022Q3 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
127821000
CY2021Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
115422000
CY2021Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
11000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p>
CY2021Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22024000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p>
CY2021Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
115411000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
30000000.0
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15100000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
5000000.0
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96860000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1515000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98375000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2021 us-gaap Restructuring Costs
RestructuringCosts
2600000
CY2022Q3 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
128030000
CY2022Q3 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
209000
CY2022Q3 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
127821000
CY2021Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
115422000
CY2021Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
11000
CY2021Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
115411000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
30000000.0
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15100000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
5000000.0
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96860000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1515000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98375000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9670000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623309
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3585000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5022000
CY2022Q3 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7768000
CY2021Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3719000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
675000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
727000
CY2022Q3 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
501000
CY2021Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1482000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12529000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5400000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2022Q3 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.074
CY2021Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
204000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1380000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
204000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2189000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5022000
CY2022Q3 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7768000
CY2021Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3719000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
675000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
727000
CY2022Q3 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
501000
CY2021Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1482000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12529000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5400000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2022Q3 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.074
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3504675
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.14
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
79837
CY2021Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
204000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1380000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
204000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2746000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5571000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2746000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2746000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5571000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2746000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21024000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38608000
CY2022Q3 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1000000
CY2021Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22024000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2021 us-gaap Restructuring Costs
RestructuringCosts
2600000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2358960
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6079071
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
583000
vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
1090000
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
225000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12096000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2075000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10021000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
583000
vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
1090000
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
225000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12096000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2075000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10021000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5693000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2581363
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.85
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2189000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9670000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2189000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9670000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37780547
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2189000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9670000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1838000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5013193
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.69
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1165000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3504675
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.14
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
79837
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2358960
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6079071
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5693000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2581363
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1838000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623309
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1062852
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37780547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38292497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5013193
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.69
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1165000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6022102
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6510200
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7084954
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6510200
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
17624000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25137000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22782000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76906000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6022102
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6510200
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7084954
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6510200
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
17624000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25137000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22782000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76906000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37780547
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623309
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38507542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37780547
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38292497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623309
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1062852
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39570394
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37780547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38292497
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623309

Files In Submission

Name View Source Status
0001558370-22-016733-index-headers.html Edgar Link pending
0001558370-22-016733-index.html Edgar Link pending
0001558370-22-016733.txt Edgar Link pending
0001558370-22-016733-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20220930.xsd Edgar Link pending
vygr-20220930x10q.htm Edgar Link pending
vygr-20220930x10q006.jpg Edgar Link pending
vygr-20220930x10q008.jpg Edgar Link pending
vygr-20220930xex31d1.htm Edgar Link pending
vygr-20220930xex31d2.htm Edgar Link pending
vygr-20220930xex32d1.htm Edgar Link pending
vygr-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
vygr-20220930_def.xml Edgar Link unprocessable
vygr-20220930_pre.xml Edgar Link unprocessable
vygr-20220930_lab.xml Edgar Link unprocessable
vygr-20220930x10q_htm.xml Edgar Link completed